A Mosaic of Uncertainty | GenomeWeb

Targeted therapies are only as good as the tests that determine whether they are warranted, says this article in the New York Times. In it, Linda Griffith, the head of MIT's Center for Gynepathology Research, says that she has seen this both as a researcher and as a patient. Her Her2 test on a breast biopsy came back as a mosaic and whether or not she should take Herceptin was unclear.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.